Back to Search Start Over

Antigen specificity and cross-reactivity drive functionally diverse anti–Aspergillus fumigatus T cell responses in cystic fibrosis

Authors :
Carsten Schwarz
Patience Eschenhagen
Henrijette Schmidt
Thordis Hohnstein
Christina Iwert
Claudia Grehn
Jobst Roehmel
Eva Steinke
Mirjam Stahl
Laura Lozza
Ekaterina Tikhonova
Elisa Rosati
Ulrik Stervbo
Nina Babel
Jochen G. Mainz
Hilmar Wisplinghoff
Frank Ebel
Lei-Jie Jia
Matthew G. Blango
Peter Hortschansky
Sascha Brunke
Bernhard Hube
Axel A. Brakhage
Olaf Kniemeyer
Alexander Scheffold
Petra Bacher
Source :
The Journal of Clinical Investigation, Vol 133, Iss 5 (2023)
Publication Year :
2023
Publisher :
American Society for Clinical Investigation, 2023.

Abstract

BACKGROUND The fungus Aspergillus fumigatus causes a variety of clinical phenotypes in patients with cystic fibrosis (pwCF). Th cells orchestrate immune responses against fungi, but the types of A. fumigatus–specific Th cells in pwCF and their contribution to protective immunity or inflammation remain poorly characterized.METHODS We used antigen-reactive T cell enrichment (ARTE) to investigate fungus-reactive Th cells in peripheral blood of pwCF and healthy controls.RESULTS We show that clonally expanded, high-avidity A. fumigatus–specific effector Th cells, which were absent in healthy donors, developed in pwCF. Individual patients were characterized by distinct Th1-, Th2-, or Th17-dominated responses that remained stable over several years. These different Th subsets target different A. fumigatus proteins, indicating that differential antigen uptake and presentation directs Th cell subset development. Patients with allergic bronchopulmonary aspergillosis (ABPA) are characterized by high frequencies of Th2 cells that cross-recognize various filamentous fungi.CONCLUSION Our data highlight the development of heterogenous Th responses targeting different protein fractions of a single fungal pathogen and identify the development of multispecies cross-reactive Th2 cells as a potential risk factor for ABPA.FUNDING German Research Foundation (DFG), under Germany’s Excellence Strategy (EXC 2167-390884018 “Precision Medicine in Chronic Inflammation” and EXC 2051-390713860 “Balance of the Microverse”); Oskar Helene Heim Stiftung; Christiane Herzog Stiftung; Mukoviszidose Institut gGmb; German Cystic Fibrosis Association Mukoviszidose e.V; German Federal Ministry of Education and Science (BMBF) InfectControl 2020 Projects AnDiPath (BMBF 03ZZ0838A+B).

Subjects

Subjects :
Immunology
Pulmonology
Medicine

Details

Language :
English
ISSN :
15588238
Volume :
133
Issue :
5
Database :
Directory of Open Access Journals
Journal :
The Journal of Clinical Investigation
Publication Type :
Academic Journal
Accession number :
edsdoj.952a35bb46204b4d99016140937e7c30
Document Type :
article
Full Text :
https://doi.org/10.1172/JCI161593